Encyclopedia of Signaling Molecules

Living Edition
| Editors: Sangdun Choi

B Lymphocyte Antigen CD19

  • Rashmi KumarEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-6438-9_101837-1


Historical Background

CD19 was first identified as biomarker of normal and neoplastic B lymphocytes as B4 antigen with the use of anti-B4 monoclonal antibody against CD19 (Anderson et al. 1984). Anti-B4 antibody in turn was encoded from cDNA clones of human tonsillar cDNA library, by selectively hybridizing with RNA from CD19+ cell lines. Both human and mouse CD19 molecules are highly homologous with a conserved cytoplasmic domain with no homology with other known proteins and an immunoglobulin-like extracellular domain, which gave CD19 molecule the status of a member of Ig superfamily (Tedder and Isaacs 1989).


The CD19 molecule is a 95 KDa cell surface protein of B lymphocytes and follicular dendritic cells (FDC). It is considered as a biomarker of B cell because of its continued expression throughout B cell differentiation stages starting from late pro-B cell stage until terminally differentiated plasma cells (Nadler et al. 1983;...


Chimeric Antigen Receptor CD19 Gene Common Variable Immunodeficiency Germinal Center Formation CD19 Surface Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424–33.PubMedGoogle Scholar
  2. Baracho GV, Miletic AV, Omori SA, Cato MH, Rickert RC. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011;23:178–83.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol (Baltimore, Md: 1950). 1992;149:2841–50.Google Scholar
  4. Bustelo XR. Vav family exchange factors: an integrated regulatory and functional view. Small GTPases. 2014;5:9.CrossRefPubMedGoogle Scholar
  5. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 1992;256:105–7.CrossRefPubMedGoogle Scholar
  6. Carter RH, Wang Y, Brooks S. Role of CD19 signal transduction in B cell biology. Immunol Res. 2002;26:45–54.CrossRefPubMedGoogle Scholar
  7. Del Nagro CJ, Kolla RV, Rickert RC. A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis. J Immunol (Baltimore, Md: 1950). 2005;175:5379–89.CrossRefGoogle Scholar
  8. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3:39–50.CrossRefPubMedGoogle Scholar
  9. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol. 2000;18:393–422.CrossRefPubMedGoogle Scholar
  10. Fuxa M, Busslinger M. Reporter gene insertions reveal a strictly B lymphoid-specific expression pattern of Pax5 in support of its B cell identity function. J Immunol (Baltimore, Md: 1950). 2007;178:3031–7.CrossRefGoogle Scholar
  11. Hammer O. CD19 as an attractive target for antibody-based therapy. MAbs. 2012;4:571–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10:103–6.CrossRefPubMedGoogle Scholar
  13. Kanegane H, Agematsu K, Futatani T, Sira MM, Suga K, Sekiguchi T, van Zelm MC, Miyawaki T. Novel mutations in a Japanese patient with CD19 deficiency. Genes Immun. 2007;8:663–70.CrossRefPubMedGoogle Scholar
  14. Katz BZ, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma. 2014;55:999–1006.CrossRefPubMedGoogle Scholar
  15. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992;12:2662–72.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Mei HE, Schmidt S, Dorner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012;14(Suppl 5):S1.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol. 1983;131:244–50.PubMedGoogle Scholar
  18. Otero DC, Anzelon AN, Rickert RC. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol. 2003;170:73–83.CrossRefPubMedGoogle Scholar
  19. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000;165:6635–43.CrossRefPubMedGoogle Scholar
  20. Schriever F, Freedman AS, Freeman G, Messner E, Lee G, Daley J, Nadler LM. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med. 1989;169:2043–58.CrossRefPubMedGoogle Scholar
  21. Shoham T, Rajapaksa R, Boucheix C, Rubinstein E, Poe JC, Tedder TF, Levy S. The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol. 2003;171:4062–72.CrossRefPubMedGoogle Scholar
  22. Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol. 1989;143:712–7.PubMedGoogle Scholar
  23. van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patino PJ, van Dongen JJ, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354:1901–12.CrossRefPubMedGoogle Scholar
  24. von Muenchow L, Engdahl C, Karjalainen K, Rolink AG. The selection of mature B cells is critically dependent on the expression level of the co-receptor CD19. Immunol Lett. 2014;160:113–9.CrossRefGoogle Scholar
  25. Wang Y, Brooks SR, Li X, Anzelon AN, Rickert RC, Carter RH. The physiologic role of CD19 cytoplasmic tyrosines. Immunity. 2002;17:501–14.CrossRefPubMedGoogle Scholar
  26. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Yoshizaki A, Sato S. Abnormal B lymphocyte activation and function in systemic sclerosis. Ann Dermatol. 2015;27:1–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Zhou LJ, Ord DC, Omori SA, Tedder TF. Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes. Immunogenetics. 1992;35:102–11.PubMedGoogle Scholar
  29. Zhou LJ, Smith HM, Waldschmidt TJ, Schwarting R, Daley J, Tedder TF. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol Cell Biol. 1994;14:3884–94.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2016

Authors and Affiliations

  1. 1.Nanomaterial Therapeutics and Toxicology GroupCSIR-Indian Institute of Toxicology Research (CSIR-IITR)LucknowIndia